Metastatic Breast Cancer
Why trials studying Metastatic Breast Cancer stopped, in this sample of ClinicalTrials.gov.
21 stopped trials with a clear reason; 90% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| slow accrual | 9 | 43% |
| funding business | 9 | 43% |
| regulatory | 1 | 5% |
| other | 1 | 5% |
| futility | 1 | 5% |
Trials
- A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
NCT06585969 · WITHDRAWN · funding business
“Lack of funding” - Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
NCT05954143 · TERMINATED · funding business
“Sponsor Decision” - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
NCT05191004 · WITHDRAWN · funding business
“Sponsor decision” - Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
NCT05233696 · WITHDRAWN · slow accrual
“Low Accrual” - Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
NCT04796324 · TERMINATED · funding business
“Company Decision” - Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression
NCT04251169 · TERMINATED · funding business
“The enrollment was stopped prematurely due to the lack of funding” - Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
NCT04265274 · WITHDRAWN · slow accrual
“Poor acrual” - Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
NCT03786094 · TERMINATED · futility
“The study was halted early due to failure to meet the primary endpoint.” - Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
NCT02753595 · TERMINATED · slow accrual
“evolving standard of care and difficulties of enrolling participants” - A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
NCT02423902 · TERMINATED · other
“The study was terminated after 9 subjects had enrolled under Protocol Amend 1 because of slower than expected accrual. Protocol Amendment 2 (16 May 2016) was submitted to the FDA and, based on the decision of the PI, was not submitted to the IRB.” - Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer
NCT02863146 · TERMINATED · slow accrual
“Lack of enrollment” - A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
NCT02322853 · TERMINATED · slow accrual
“lack of recruitment” - 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
NCT02000596 · TERMINATED · funding business
“funding withdrawn by sponsor” - Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer
NCT01985893 · WITHDRAWN · funding business
“Due to missing patient recruitment, the financial support was stopped.” - Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
NCT01939418 · TERMINATED · slow accrual
“slow recruitment” - Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
NCT01207102 · TERMINATED · slow accrual
“Low enrollment and there is insufficient data to publish.” - Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)
NCT01416558 · TERMINATED · slow accrual
“Study was terminated because of extrem low recruitment” - Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer
NCT00905021 · TERMINATED · funding business
“Sponsor withdrew support” - Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy
NCT00903656 · TERMINATED · funding business
“Caelyx was not available anymore” - Phase I Study of Aprotinin in Advanced Breast Cancer
NCT00354900 · TERMINATED · regulatory
“The FDA changed the labeling for this agent, and we felt we could not offer it to patients on a non-surgical study.” - To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older
NCT00082095 · TERMINATED · slow accrual
“The study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients in 20 months”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.